GCS-100 new compound studied to treat Myeloma

GlycoGenesys, Inc. is a biotechnology company focused on carbohydrate-based drug development. The Company currently is conducting a Phase I dose escalation trial of GCS-100LE, a unique compound to treat cancer, in patients with solid tumors. In addition, the Company is conducting a Phase I/II dose escalation trial of GCS-100LE in multiple myeloma at the Dana-Farber Cancer Institute in Boston, Massachusetts. Further clinical trials are planned for 2005. Additional information is available on GlycoGenesys' web site: www.glycogenesys.com.